These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 12194746

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. NRTI-related mitochondrial toxicity in an HIV-infected woman.
    Jenny-Avital ER.
    AIDS Clin Care; 2003 Oct; 15(10):87-9. PubMed ID: 14666921
    [No Abstract] [Full Text] [Related]

  • 7. Antiretroviral rounds. Putting resistance to work.
    Daar ES, Elion R.
    AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926
    [No Abstract] [Full Text] [Related]

  • 8. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
    Pujari S, Patel A, Joshi SR, Gangakhedkar R, Kumarasamy N, Gupta SB, Expert Panel 2008.
    J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE.
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA, Raskino C, Vavro C, Palumbo P, Ross LL, McKinney R, Nikolic-Djokic D, Colgrove RC, Baker CJ, Pediatric AIDS Clinical Trials Group Protocol 152 Team.
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 15. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003 Aug; 15(4):1-2. PubMed ID: 17216850
    [No Abstract] [Full Text] [Related]

  • 16. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Aug; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Top stories of 2008. Antiretroviral rollout--successes and challenges.
    Friedland GH.
    AIDS Clin Care; 2009 Jan; 21(1):5. PubMed ID: 19219959
    [Abstract] [Full Text] [Related]

  • 20. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.
    AIDS; 2008 Jul 11; 22(11):1305-12. PubMed ID: 18580610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.